KERYX BIOPHARMACEUTICALS INC
CIK 0001114220
Revenue (TTM)
—
Q3 Oct 2018
Net Income (TTM)
−$83.91M
−29.5% YoY
Q3 Oct 2018
EPS Diluted (TTM)
−$0.42
−23.5% YoY
Q3 Oct 2018
Gross Margin
—
Q3 Oct 2018
Operating Margin
—
Q3 Oct 2018
Net Margin
—
Q3 Oct 2018
Free Cash Flow (TTM)
−$36.5M
Q3 Oct 2018
Cash
$41.15M
Q3 Oct 2018
Total Debt
—
Q3 Oct 2018
Shares Outstanding
102.38M sh
Q3 Oct 2018
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.